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Background: No previous meta-analysis was to report the association between the apolipoprotein B (APOB) XbaI
and EcoRI polymorphisms and serum lipids in Chinese. We performed the study to investigate their potentially
association.
Methods and Results: Studies in English and Chinese were found via a systematic search of Pubmed, Embase,
CNKI and Wanfang databases. The dominant genetic model and random-effects model were used to pool data
from individual studies. As a result, a total of 30 articles with 5611 subjects for XbaI and 2653 subjects for EcoRI
were included in the current study. For the XbaI polymorphism, overall, subjects carrying X+ allele were significantly
associated with higher TC,TG and LDL compared with X-X- genotype (Pvalue =0.0006, OR (95 %) = -0.55 (-0.86,-0.23);
Pvalue = 0.0004, OR (95 %) = -0.30 (-0.47,-0.14); (Pvalue = 0.05, OR (95 %) = -0.23(-0.46,-0.00), respectively).
Similar results were observed in the subgroups of Han, healthy individuals (HT), coronary heart disease (CHD),
cerebral infarction (CI), and cholelithiasis. For HDL, positive association between X+ allele with Lower lipid
value was found in CHD and CI subgroups. For EcoRI polymorphism, overall, the E- allele carriers were found
to be obviously linked with elevated LDL and lower HDL compared with E + E+ genotype (Pvalue = 0.02,OR
(95 %) = -0.27 (-0.49,-0.05); Pvalue = 0.01, OR (95 %) = 0.17 (0.03, 0.30), respectively). TC was significantly high
in subjects carrying E- allele in the subgroup of hyperlipidemia. No evidence of publication bias was observed.
Conclusions: The two genetic variants of APOB may be associated with serum lipids in Chinese.
Keywords: Apolipoprotein B or APOB, Chinese, Lipid, PolymorphismIntroduction
Many epidemiological studies have reported that meta-
bolic disorders in serum lipids are considerable risk factors
for premature coronary artery disease and atherosclerosis
[1]. Serum lipids are multifactorial that emphasize the
contribution of genetic as well as environmental factors.
Genetically determined variation has been shown to have
a close relationship with the metabolism abnormality of
lipids and the pathogenesis of atherosclerosis [2, 3]. Al-
though no convincing gene has been found to be of the
importance for lipids, the obvious candidate genes are still
necessary for a better understanding of lipid metabolism.* Correspondence: anzhenwensj@sina.com
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the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeApolipoprotein B (APOB) is an important protein
component in contribution to intermediate density lipopro-
tein, the formation of very low density lipoprotein, low
density lipoprotein particle, and is related to the clearance
of LDL in serum. Beside these, it mediates cellular uptake
of cholesterol and is the ligand that binds to the LDL recep-
tor [4]. The gene coding for APOB has been cloned and is
located on the short arm of chromosome 2 (q23q24). Many
variants of the APOB gene has been found to be directly
linked with lipid levels. In our study, among these variants,
we paid particular attention to the most investigated XbaI
(rs693 ) in exon 26 and EcoRI (rs1042031) in exon 29 single
nucleotide polymorphisms in the APOB gene.
A meta-analysis by Boekholdt et al. [5] ten years ago
had showed the relationship between the XbaI and EcoRI
polymorphisms and lipids in Caucasian subjects. However,
no meta-analysis about their association has concentratedistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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background between Caucasian and Chinese may result in
different findings. Moreover, the results of many published
papers for the two polymorphisms in Chinese were incon-
clusive. Some of them showed strong associations between
the XbaI and EcoRI polymorphisms in the APOB gene
and serum lipids, whereas others had null association.
Therefore, we performed a systematic meta-analysis of all
eligible studies investigating the APOB XbaI and EcoRI
polymorphisms and their association with serum lipids in
Chinese.
Methods
Literature search and selection criteria
To identify the studies evaluating the relationship between
the APOB XbaI and EcoRI polymorphisms and lipid profile
in Chinese, a computerized literature search of PubMed,
EMBASE, Wanfang and CNKI databases was carried
out, applying the following keywords: ‘apolipoprotein B
or APOB’, ‘polymorphism’, ‘lipid’, ‘Chinese or China or
Taiwanese or Taiwan’ (up to September 1, 2015). The
articles in English and Chinese would be included.
References of the relevant articles were also examined.
If multiple articles used the same data, only the more
detailed one was selected. The included studies should
be accordance with the later criteria: (i) studies evaluat-
ing the association of the APOB XbaI and EcoRI poly-
morphisms with lipids in Chinese, (ii) At least one of
the lipid phenotypes was measured: total cholesterol
(TC), triglyceride (TG), low density lipoprotein(LDL), and
high density lipoprotein(HDL), (iii) Sufficient data involving
genotype frequency as well as mean and standard deviation
(SD) of lipids, (iv) If the article was a retrospective case-
control study, each population (case/control groups) was
treated as a single study and genotype frequency among
control populations must be tested for Hardy-Weinberg
equilibrium (HWE). If the genotype frequency was not
supplied or calculated, the writers of these papers would
be contacted by emails.
Data extraction
Two of the authors extracted the information from each
study independently. Inconsistencies were discussed
between the authors to reach an agreement. For each
study, the following information would be collected: first
author, year, ethnicity, resident region, detection method,
sample size, character of participants, and lipid phenotypes
of each study.
Statistical analysis
In our study, standardized mean difference (SMD) with
their 95 % CIs were used to measure the strength of the
association of the APOB XbaI and EcoRI polymorphisms
with lipids. For the two polymorphisms, we tested thedominant genetic model (X-X- vs. X + X-/X + X+, E + E+
vs. E + E-/E-E-), because the low frequency of homozy-
gosity for the mutant alleles would yield a large number
of studies with zero cell counts, leading to the unreliable
estimates, and the X + X-/X + X+ and E + E-/E-E- geno-
types in most studies were combined into one group.
The random-effects model was used to assess the pooled
estimates and the significance of the pooled estimates
was determined using a Z-test. Heterogeneity among
studies was assessed by the X2-based Q-statistic test
and considered significant for P < 0.10 [6]. Subsequently
based on racial ground, subgroup analysis was undertaken
for Han and non-Han minority in Chinese. In addition,
subgroup analysis for the XbaI polymorphism was also
planned for healthy individuals (HT), coronary heart dis-
ease (CHD), cerebral infarction(CI), hyperlipidemia and
cholelithiasis. Subgroup analysis for the EcoRI polymorph-
ism was performed for healthy individuals (HT), coronary
heart disease (CHD) and hyperlipidemia. Each subgroup
had at least three independent studies. Sensitivity analysis
was carried out by removing a single study each time in
order to find out whether any single study could bias the
overall estimate. Sensitivity analysis were used to detect
the cause of heterogeneity when the between-study het-
erogeneity would exist. Finally, we evaluated publication
bias by funnel diagram. The funnel diagram asymmetry,
suggesting publication bias, was precisely assessed by
Egger’s linear regression test and Begg’s rank correlation
test [7, 8] we re-calculated HWE using a web program
(http://ihg.gsf.de/cgi-bin/hw/hwal.pl). All data were ana-
lyzed with Review Manager 5.0 (Oxford, UK) and STATA
12.0 (Stata Corp., TX, USA). All P values reported were
two-sided, and a significance level of less than 0.05 was
considered statistically significant.
Results
Inclusion and characteristics of studies
As a beginning analysis, 77 relevant articles were found
after literature search and selection. Among these se-
lected studies, 43 articles were removed because their
data were overlapping or duplicated. One paper [9] was
deleted due to meta-analysis and two [10, 11] were ex-
cluded due to lack of the available information. For the
EcoRI polymorphism, the data from 3 studies [12–14]
was excluded as they deviated from HWE. Finally, the
remaining 30 articles [13–42] with 5611 subjects for
XbaI and 2653 subjects for EcoRI were included in this
meta-analysis. Among them, Fan et al. [18] was an un-
published theses from the dissertation database, that is,
an open sub-database shared by Wanfang and CNKI. 14
articles [14–16, 20, 22, 24, 27, 28, 30–34, 36] provided
the available data on case and controls, which would be
respectively handled as the separate two studies for each
analysis. For all eligible studies, HWE had been recounted
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studies were showed in Table 1.
In our study, based on the available genotype and al-
lele frequency, we observed that, the X+ allele frequency
of XbaI was 7.0 % in the whole population, and the E-
allele frequency of EcoRI was 8.0 %, which both obviously
had a lower frequency of the mutant allele than the
Caucasian population.
Association of the XbaI polymorphism with various lipids
The results of the relationship between the APOB XbaI
ploymorphism and lipids in Chinese were shown in Table 2.
In this analysis of TC, 5468 subjects (37 studies) were in-
cluded. Overall, we observed that, TC was significantly highTable 1 Main characteristics of the included studies in the meta-ana
First author,year Ethnicity Region Sample size
Bai, [15]2008 Han Ningxia 165
Chai, [16] 1996 Han Shanghai 82
Evans, [17] 1993 Han Shanxi 143
Fan, [18] 2009 Han Fujian 387
Guo, [19] 1996 Han Liaoning 55
Han, [20] 2000 Han Shanghai 631
Hu, [21] 2008 Han Guangxi 150
Hu, [13] 2009 Han Guangxi 200
Ji,[22] 2014 Han Inner mongolian 120
Li, [23] 1997 Han Tianjing 71
Liu, [24] 2008 Han Hunan 230
Liu, [25] 2010 Han Shanghai 186
Liu,[26] 2014 Li/Han Hainan 351
Ma, [27] 2012 Yao Guangdong 500
Pan, [28] 1995 Han Taiwan 301
Saha, [29] 1992 Han Singapore 196
Tan, [30] 2003 Han Jiangsu 211
Wang, [31] 1999 Han Beijing 377
Wei, [32] 2001 Han Sichuan 169
Xie, [33] 2010 Han Xinjiang 300
Yan, [34] 2003 Han Beijing 257
Yao, [14] 1999 Han Jiangsu 141
Yao, [35] 2005 Han Xinjiang 112
Ye, [36] 1995 Han Beijing 203
Ye, [37] 2003 Han Beijing 88
Zhang, [39] 2009 Han Hunan 130
Zhang,[38] 2010 Han Xinjiang 154
Zhang, [40] 2015 Han Beijing 82
Zhao, [41] 1997 Han Beijing 117
Zhu, [42] 2001 Han Beijing 308
CA carotid atherosclerosis, HT healthy individuals, CI cerebral infarction, PNS primary
reaction-restriction fragment length polymorphism, TC total cholesterol, TG triglycerin subjects carrying X+ allele compared with X-X- genotype
(Pvalue = 0.0006, OR (95 %) = −0.55 (−0.86,−0.23)). Similar
findings were seen in the subgroups of Han (Pvalue = 0.001,
OR (95 %) = −0.59 (−0.94,−0.24)), CI (Pvalue = 0.007, OR
(95 %) = −0.85 (−1.46,−0.24)) and cholelithiasis (Pvalue =
0.004, OR (95 %) = −0.54 (−0.91,−0.18)). However, no posi-
tive association was obtained in the subgroups of non-Han
minorities, HT, CHD, and hyperlipidemia. For the TG ana-
lysis, 5425 subjects (37 studies) were collected. In the whole
population, X+ allele carriers were found to be obviously
associated with higher TG value compared with X-X- geno-
type (Pvalue =0.0004, OR (95 %) = −0.30 (−0.47,−0.14)).
Similar results were observed in the subgroups of Han
(Pvalue = 0.0009, OR (95 %) = -0.32 (-0.50,-0.13)), HTlysis
SNPs Character of subjects Method Lipid profile
EcoRI CA/HT PCR-RFLP TC,TG,LDL,HDL
XbaI CI/HT PCR-RFLP TC,TG,LDL,HDL
XbaI HT PCR-RFLP TG,LDL,HDL
XbaI Hyperlipidemia PCR-RFLP TC,TG,LDL,HDL
XbaI CI PCR-RFLP TC,TG,LDL,HDL
XbaI Cholelithiasis/HT PCR-RFLP TC,TG,LDL,HDL
XbaI PNS PCR-RFLP TC,TG,LDL,HDL
XbaI HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI Cholelithiasis/HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI CHD PCR-RFLP TC,TG,LDL,HDL
EcoRI CI/HT PCR-RFLP TC,TG,LDL,HDL
XbaI Gastric cancer PCR-RFLP TC,LDL
XbaI HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI Hyperlipidemia/HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI CHD/HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI Cholelithiasis/HT PCR-RFLP TC,TG,LDL,HDL
XbaI CI/HT PCR-RFLP TC,TG,LDL,HDL
XbaI Cholelithiasis/HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI Hyperlipidemia/HT PCR-RFLP TC,TG,LDL,HDL
EcoRI CHD/HT PCR-RFLP TC,TG,LDL,HDL
XbaI CI/HT PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI fatty liver DNA chips TC,TG,LDL,HDL
XbaI CHD/HT PCR-RFLP TC,TG,LDL,HDL
XbaI Hyperlipidemia PCR-RFLP TC,TG,LDL
XbaI CI PCR-RFLP TC,TG,LDL,HDL
EcoRI CHD PCR-RFLP TC,TG,LDL,HDL
EcoRI,XbaI Hyperlipidemia PCR-RFLP TC,TG,LDL,HDL
XbaI CI PCR-RFLP TC,TG,LDL,HDL
XbaI HT PCR-RFLP TC,TG,LDL,HDL
nephrotic syndrome, CHD coronary heart disease, PCR-RFLP polymerase chain
ide, LDL low density lipoprotein, HDL high density lipoprotein
Table 2 Overall and subgroup associations of the APOB XbaI polymorphism and lipids
Lipids Overall or subgroups Studies Subjects OR (95 %) Pvalue Pheterogenity Pe
TC Overall 37 5468 −0.55[−0.86,−0.23] 0.0006 <0.01 0.08
Han 34 4812 −0.59[−0.94,−0.24] 0.001 <0.01
Non-Han minorities 3 651 −0.25[−0.61, 0.10] 0.16 0.08
HT 16 2708 −0.61[−1.3, 0.07] 0.08 <0.01
CHD 3 322 0.02[−0.37, 0.42] 0.90 0.71
CI 6 577 −0.85[−1.46,−0.24] 0.007 <0.01
Hyperlipidemia 5 957 −0.24[−0.71, 0.22] 0.31 <0.01
Cholelithiasis 4 456 −0.54[−0.91,−0.18] 0.004 0.11
TG Overall 37 5425 −0.30[−0.47,−0.14] 0.0004 <0.01 0.25
Han 34 4774 −0.32[−0.50,−0.13] 0.0009 <0.01
Non-Han minorities 3 651 −0.19[−0.41, 0.02] 0.08 0.98
HT 17 2851 −0.31[−0.62, 0.00] 0.05 <0.01
CHD 3 322 −0.53[−0.93,−0.13] 0.009 0.41
CI 6 577 −0.50[−1.02, 0.02] 0.06 0.0001
Hyperlipidemia 5 957 −0.29[−0.62, 0.04] 0.09 0.01
Cholelithiasis 4 456 −0.11[−0.34, 0.12] 0.36 0.86
LDL Overall 38 5611 −0.23[−0.46,−0.00] 0.05 <0.01 0.80
Han 35 4960 −0.23[−0.49, 0.03] 0.09 <0.01
Non-Han minorities 3 651 −0.26[−0.47,−0.04] 0.02 0.5
HT 17 2851 −0.21[−0.60, 0.18] 0.29 <0.01
CHD 3 322 0.15[−0.25, 0.54] 0.47 0.6
CI 6 577 −0.52[−1.08, 0.05] 0.07 <0.01
Hyperlipidemia 5 957 0.15[−0.47, 0.78] 0.63 <0.01
Cholelithiasis 4 456 −0.4[−0.64,−0.17] 0.0007 0.46
HDL Overall 36 5337 0.17[−0.08, 0.41] 0.18 <0.01 0.86
Han 33 4686 0.15[−0.12, 0.43] 0.27 <0.01
Non-Han minorities 3 651 0.24[0.01, 0.47] 0.04 0.33
HT 17 2851 0.11[−0.43, 0.64] 0.07 <0.01
CHD 3 322 0.50[0.11, 0.90] 0.01 0.78
CI 6 577 0.43[0.13, 0.74] 0.005 0.11
Hyperlipidemia 4 869 0.10[−0.08, 0.27] 0.27 0.97
Cholelithiasis 4 456 −0.10[−0.33, 0.13] 0.40 0.78
TC total cholesterol, TG triglyceride, LDL low density lipoprotein, HDL high density lipoprotein, HT healthy individuals, CHD coronary heart disease,
CI cerebral infarction
Pvalue: the significance of the pooled estimate (95 % confidence interval)
Pheterogeneity: the Q statistic for heterogeneity
Pe: Egger’s statistic for publication bias
All results were calculated under the dominant genetic model (X-X- vs. X + X-/X + X+)
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(Pvalue = 0.009, OR (95 %) = −0.53 (−0.93,−0.13)). There
was no evidence of correlation in the subgroup of non-Han
minorities, CI, cholelithiasis and hyperlipidemia.
For LDL, 5611 subjects (38 studies) were collected.
Overall, a marginally positive association between X+
allele with higher lipid value was found (Pvalue = 0.05,
OR (95 %) = −0.23 (−0.46,−0.00), Fig. 1). In the subgroup
analysis, we also observed the significant association innon-Han minorities (Pvalue = 0.02, OR (95 %) = −0.26
(−0.47,−0.04)) and cholelithiasis (Pvalue = 0.0007, OR
(95 %) =−0.4 (−0.64,-0.17)). No statistically significant
differences were found in the subgroups of Han, HT, CHD,
CI and hyperlipidemia. Finally for HDL, 5337 subjects
(36 studies) were analyzed. No significant association
was observed in the overall and in the subgroups of Han,
HT, hyperlipidemia and cholelithiasis. In the non-Han mi-
norities, CHD and CI subgroups, subjects carrying X+ allele
Fig. 1 Association between the APOB XbaI polymorphism and LDL under the dominant genetic model (X-X- vs. X + X-/X + X+). “X-“ represents
the X-X- genotype; X+ represents the X + X-/X + X+ genotypes
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0.04, OR (95 %) = 0.24 (0.01, 0.47); Pvalue = 0.01, OR
(95 %) = 0.50 (0.11, 0.90; Pvalue = 0.005, OR (95 %) = 0.43
(0.13, 0.74), respectively ).
Association of the EcoRI polymorphism with various lipids
The results of the relationship between the APOB EcoRI
ploymorphism and lipids in Chinese were shown in Table 3.
For TC, 2653 subjects (21 studies) were included. A
significant association of the E- allele with higher TC was
detected in the subgroup of hyperlipidemia (Pvalue < 0.01,
OR (95 %) = −0.56 (−0.78,−0.35)). There was no difference
in the whole population and in the subgroups of Han,
HT and CHD. For TG, 2653 subjects (21studies) were
assessed. We found no significant association between
the EcoRI ploymorphism and TG in overall and even in
the subgroup analysis. For LDL, 2653 subjects (21 studies)were found. Overall, subjects carrying the E- allele were
found to be obviously linked with higher LDL compared
with E + E+ genotype (Pvalue = 0.02, OR (95 %) = −0.27
(−0.49,−0.05), Fig. 2). Similar result was also shown in
the subgroup of Han (Pvalue = 0.04, OR (95 %) = −0.28
(−0.53,−0.02)). In the subgroups of HT, CHD and hyper-
lipidemia, no significant association was found. For the
HDL analysis, 2653 subjects (21studies) were included.
Overall, HDL was significantly low in subjects carrying the
E- allele compared with E + E+ genotype (Pvalue = 0.01, OR
(95 %) = 0.17 (0.03, 0.30)). However, in all the subgroups,
there was no significant association.
Sensitivity analysis
In the sensitivity analysis, we deleted one study at a time
and found whether there was a individual study affecting
the pooled SMD and the between-study heterogeneity.
Table 3 Overall and subgroup associations of the APOB EcoRI polymorphism and lipids
Lipids Overall or subgroups Studies Subjects OR (95 %) Pvalue Pheterogenity Pe
TC Overall 21 2653 −0.28[−0.58,0.01] 0.06 <0.01 0.64
Han 19 2153 −0.27[−0.61,0.07] 0.11 <0.01
HT 9 1142 −0.19[−0.89,0.52] 0.61 <0.01
CHD 4 529 −0.25[−0.56,0.05] 0.1 0.29
Hyperlipidemia 3 482 −0.56[−0.78,−0.35] <0.01 0.45
TG Overall 21 2653 −0.14[−0.32,0.03] 0.11 0.003 0.62
Han 19 2153 −0.14[−0.34,0.07] 0.19 0.001
HT 9 1142 −0.01[−0.35,0.34] 0.97 0.002
CHD 4 529 −0.26[−0.55,0.04] 0.09 0.33
Hyperlipidemia 3 482 −0.15[−0.49,0.18] 0.37 0.11
LDL Overall 21 2653 −0.27[−0.49,−0.05] 0.02 <0.01 0.51
Han 19 2153 −0.28[−0.53,−0.02] 0.04 <0.01
HT 9 1142 −0.26[−0.59,0.07] 0.13 0.005
CHD 4 529 −0.21[−0.73,0.31] 0.43 0.01
Hyperlipidemia 3 482 −0.36[−0.88,0.15] 0.17 0.006
HDL Overall 21 2653 0.17[0.03, 0.30] 0.01 0.2 0.44
Han 19 2153 0.13[−0.02, 0.28] 0.09 0.2
HT 9 1142 0.13[−0.09, 0.35] 0.25 0.25
CHD 4 529 0.24[−0.03, 0.52] 0.08 0.5
Hyperlipidemia 3 482 −0.03[−0.44,0.38] 0.89 0.04
TC total cholesterol, TG triglyceride, LDL low density lipoprotein, HDL high density lipoprotein, HT healthy individuals, CHD coronary heart disease
Pvalue: the significance of the pooled estimate (95 % confidence interval)
Pheterogeneity: the Q statistic for heterogeneity
Pe: Egger’s statistic for publication bias
All results were calculated under the dominant genetic model (E + E+ vs. E + E-/E-E-)
Fig. 2 Association between the APOB EcoRI polymorphism and LDL under the dominant genetic model (E + E+ vs. E + E-/E-E-). “E + “ represents
the E + E+ genotype; E- represents the E + E-/E-E- genotypes
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study did not obviously affect the heterogeneity and it
still exist. However, the overall pooled SMD of LDL was
apparently changed with the elimination in turn of eight
studies (Chai- HT et al. [16], Guo et al. [19], Li et al.
[23], Saha et al. [29], Yao et al. [35], Ye-CHD et al. [36],
Ye et al. [37], and Zhang et al. [40]) (data not shown).
For the EcoRI polymorphism, no individual study had an
obvious influence on the between-study heterogeneity.
After removing Saha et al. [29] for TC as well as Pan-HT
et al. [28] and Saha et al. [29] for TG, the related overall
pooled SMDs were changed (data not shown).
Finally, no significant publication bias was revealed under
the dominant genetic model for XbaI (P = 0.08 for TC, 0.25
for TG, 0.8 for LDL, 0.86 for HDL, Table 2) and for EcoRI
(P = 0.64 for TC, 0.62 for TG, 0.51 for LDL, 0.44 for HDL,
Table 3).
Discussion
Some discrepancies could be caused by differences in
ethnic background. Thus, we restricted the analysis to the
Chinese population and performed a meta-analysis con-
taining 30 articles with 5611 participants for XbaI and
2653 participants for EcoRI to more precisely understand
the relationship between these polymorphisms and lipids
in Chinese. So far this meta-analysis was the largest one
investigating the association of these two polymorphisms
in the AOPB gene with lipid level in Chinese. In the
present study, we found that, X+ allele of the XbaI poly-
morphism was significantly associated with higher TC,TG
and LDL in all subject, and E- allele of the EcoRI poly-
morphism was obviously associated with higher LDL and
lower HDL level. Our results involving XbaI were partially
consistent with the findings of the previous meta [5]. The
difference on the results about EcoRI may be due to the
distinct genetic backgrounds of the included populations.
The XbaI polymorphism within the coding region of
APOB mRNA is caused by a silent cytosine to thymine
mutation in the third base of the threonine codon at
residue 2488 in the mature APOB protein, and this site
itself is of dubious functional significance. Nevertheless,
this polymorphism may be a genetic indicator in linkage
disequilibrium with other functional mutations in the
APOB gene or a nearby-located gene [43, 44], which can
affect the metabolism of serum lipids. Compared with
X-allele, X+ allele carriers with higher LDL may be ex-
plained by differing clearance by the receptor-mediated
pathway of LDL catabolism, and with higher TC/TG may
be attributable to the production of a relatively receptor-
inactive APOB in the mutational group [45]. As a matter
of fact, many studies have reported that, compared with
the wild-type genotype, subjects with X+ allele have appar-
ently higher TC,TG, APOB and LDL levels [5, 46, 47]. The
APOB EcoRI polymorphism in the coding sequence couldresult in an acidic basic amino acid substitution, which is
non-conservative and has putative importance in APOB
protein function [48]. E+ allele carriers in association with
abnormal lipid parameters were observed in many studies
compared with E- allele carriers [5, 13]. Taken together,
APOB plays a critical role in the lipid transport. If the gene
encoding APOB has mutational changes, APOB structure
and function would be affected and finally lead to lipid
metabolism disorder, such as increase of plasma ApoB
and LDL, decrease of HDL, etc.
For the Han subgroup, owing to the largest ethnic in
Chinese and most related studies included in our meta,
the association between the XbaI and EcoRI polymorphism
and lipids was largely consistent with the results in the
whole population. Irregular results involving the non-Han
minorities in Chinese was seemingly understandable in a
complex genetic background and limited number of stud-
ies. Studies in a larger population based on a single minor-
ity are needed for a more clear observation. For the
subgroups of HT, CHD, CI and cholelithiasis in the XbaI
analysis, our finding were partially in accordance with the
published four articles [5, 9, 49-50]. In addition, hyperlipid-
emia was diagnosed when one of the following four lipids
(TC、LDL、HDL and TG ) was more than the normal
serum level, and thus the statistical power of the single lipid
(such as LDL) to detect differences may be limited due to
the smaller involved sample size. For EcoRI, when consider-
ing the subgroup analysis of hyperlipidemia, the conclusion
may be influenced and should be treated with caution, be-
cause sample size of the subgroup as well as study number
were relatively small (482 and 3, respectively).
Future related studies in this area should consider
several limitations in the present meta-analysis. Firstly,
a significant heterogeneity was detected in the analysis, and
its contributors may be population source, study design,
etc. Secondly, due to the limited number of studies at this
time, the subgroup analysis on non-Han minority popula-
tions (such as Yao) can not be well done. Thirdly, the ana-
lysis did not focus on the detailed functional research of the
studied two polymorphisms. Finally, beside genetic influ-
ence, the relationship between APOB single nucleotide
polymorphisms and lipid profile was also affected by many
environmental factors that didn’t be fully conducted in this
study, which possibly confounded the results.
In conclusion, our meta-analysis showed significant as-
sociation between the APOB XbaI polymorphism and
lipids (TC, TG and LDL) in Chinese. Similar conclusions
were observed in the subgroups of Han, HT, CHD, CI and
cholelithiasis. For the AOPB EcoRI polymorphism, the E-
allele carriers may be a genetic factor for higher LDL and
lower HDL levels in Chinese. Additional studies with lar-
ger sample size should be conducted in Chinese to make
clear the association of APOB SNPs with lipids. Studies in-
vestigating their detailed function were equally needed.
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